Method and composition for alleviating or preventing ischemic tissue damage
OwnerJeffrey E. Thomasinventor
Life of this patent
Estimating the term…
Abstract
A method for increasing collateral circulation includes providing a pharmaceutically acceptable synthetic cerebrospinal fluid that has a density different than that of the patient's naturally-occurring cerebrospinal fluid. The synthetic cerebrospinal fluid includes a vasodilator. The method further includes administering the synthetic cerebrospinal fluid to an intrathecal space of a patient through a lumbar access point to reach the intrathecal space of a patient.
Claims20
A method for increasing collateral circulation:
- providing a pharmaceutically acceptable synthetic cerebrospinal fluid which is hyperbaric with respect to naturally-occurring cerebrospinal fluid, said synthetic cerebrospinal fluid comprising a vasodilator;
- and
- administering said synthetic cerebrospinal fluid to an intrathecal space of a patient using a lumbar access point to access said intrathecal space.
A method for treating an individual suspected of having a cerebrovascular event comprising:
- providing a quantity of synthetic cerebrospinal fluid having a density different from the density of the individual's naturally-occurring cerebrospinal fluid;
- mixing a vasodilator with the quantity of synthetic cerebrospinal fluid;
- and
- administering the synthetic cerebrospinal fluid vasodilator mixture to an intrathecal space of the individual.
A method for treating or preventing ischemic damage comprising:
- providing a pharmaceutically acceptable carrier fluid having a first density, said first density being different than a specific density of the patient's naturally-occurring cerebrospinal fluid, said carrier fluid comprising a vasodilator;
- and
- administering said carrier fluid to an intrathecal space of a patient;
- wherein said first density of said carrier fluid facilitates transfusion of the vasodilator throughout the intrathecal space of the patient.
A composition for increasing collateral circulation in a patient, comprising:
- a pharmaceutically acceptable synthetic cerebrospinal fluid, a density altering agent, and a vasodilator;
- wherein composition includes a density, said density being different from a density of a patient's naturally-occurring cerebrospinal fluid.
Dependencies are inferred from the claim text.